TINC Spring 2024
| Reference number | |
| Coordinator | Aasa Health AB |
| Funding from Vinnova | SEK 73 500 |
| Project duration | April 2024 - May 2024 |
| Status | Completed |
| Venture | Acceleration |
Important results from the project
The goal of expanding our network and expanding our presence on the American market has been achieved. The goal of increasing sales in the American market is underway. We have had several meetings with researchers, potential customers, investors and experts in American healthcare that help us improve our go-to-market strategy, marketing and sales strategies, and started contacts with researchers in the USA. We expect that this will lead to increased sales, credibility and expansion in the American market.
Expected long term effects
We participated in the TINC 2024 program for a total of 5 weeks, where 4 weeks were conducted digitally from Sweden and then we spent a week in Palo Alto, CA. There we spent the days in meetings, workshops, seminars and other events together with other startup companies, experts, investors, potential customers and researchers. We have been able to network and introduce Vitala to several key stakeholders and will be able to take this further to improve our expansion into the US market.
Approach and implementation
Under TINC 2024 we had 4 weeks of digital workshops with experts within TINC´s network. These focused on strategies in marketing, sales, go-to-market, expansion, hiring the dream team, as well as several other areas. Then we spent a week in Palo Alto, CA together with other startup companies. In Palo Alto, we had several meetings with potential customers, investors, experts, founders and other people who help us with our strategies to expand to the American market.